

### (FUSUNPHARM) 复星医药

### 上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(Stock Code: 02196)

£ .C

#### 2013 THIRD QUARTERLY REPORT

B OF F B F
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*
Chen Qiyu

C  $\mathcal{L}$ 

\* F .C, .C,

#### **§1 IMPORTANT NOTICE**

- $1.2\ A_{11}\ D_{_{1}}\mathcal{F}_{_{1}}\ldots\mathcal{F}_{_{n}}\ldots\mathcal{F}_{_$

- §2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDERS OF THE COMPANY
- $2.1~M_{\parallel}~,~\mathcal{F}_{\parallel}~,~\dots,~\mathcal{F}_{\parallel}~,~\dots,~\mathcal{F}_{\parallel}~,~\dots$

1	

# A , $\mathcal F$ , $\tau$ , $_{\lambda},\tau$ , $\mathcal F$ , $\mathcal F$ , $\mathcal F$ , $_{\lambda},_{\parallel}\mathcal F$ , $_{m-\parallel},_{m-\parallel}m$ , . :

Items	The Reporting Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period	Description
G_1,, t	10,251,236.77	596,825,644.44	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2,878,850.90	13,168,079.40	
$ \frac{G}{G} = \{ \frac{1}{2}, \frac{1}{4}, \dots, \frac{1}{2}, \frac{1}{2}, \dots, \frac{1}{2}, \frac{1}{4}, \frac{1}{4}, \dots, \frac{1}{2}, \dots, \frac{1}{4}, \frac{1}{4}, \dots, \frac{1}{4$			

The Top 10 unrestricted shareholders of trad	able shares	
Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
$S_{-1}$ , $I_{-1}$ , $F_{-1}$ , $H_{1}$ , $T_{-1}$ , $\dots$ $I_{-1}$ , $G_{-1}$ , $G$	920,641,314	RMB F F
HKSCC NOMINEES LIMITED (.C. )	335,255,500	O , F ,
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	37,868,964	RMB . F . F . F
C . C . F . B . — H A H . L S . S . I . m . F .	32,188,808	RMB F F
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	21,318,308	RMB . F . F
$\frac{I_{-1} \cdot I_{-1} \cdot I_{-1} \cdot C_{-mm} \cdot I_{-1} \cdot B_{1} \cdot \cdot C_{-m-1} - I_{-1} \cdot S_{-1} \cdot G_{-1} \cdot f_{-1} \cdot \cdot b_{1} \cdot \cdot S_{-m}}{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot S_{-1} \cdot G_{-1}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1} \cdot I_{-1} \cdot \cdot S_{-m}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1} \cdot I_{-1}} \cdot \frac{S_{-1} \cdot I_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1} \cdot I_{-1}} \cdot \frac{S_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1} \cdot I_{-1}} \cdot \frac{S_{-1} \cdot I_{-1}}{F_{1} \cdot I_{-1}} \cdot \frac{S_{-1} \cdot $	19,120,000	RMB , F , F
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	18,110,252	$RMB \cdot \mathcal{F}_{x \mid x} = \mathcal{F}$
$N_{1,2,\dots,1}$ $S_{1,2,1}$ $S_{2,1}$ $F_{1,1}$ $F_{1,2}$ $F_{1,1}$ $F_{2,1}$ $F_{2,1}$	16,599,805	RMB F F
B C	10,199,839	RMB F F
$B_{\cdot,\cdot,\cdot}$ $C_{\cdot,\cdot,\cdot,\cdot}$ $C_{\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,\cdot,$	10,000,000	RMB F F
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	T b I T T C C C T SO O C F B C M	S   T   I   m   C

IL

#### **§3 SIGNIFICANT EVENTS**

$$3.1 \quad S_{I_{-1}, I_{-1}, \dots, I_{$$

...: r<sub>|</sub>. Cr 既...: RMB

		Balance Sl	not	<u>'</u>
_	Closing balance as at the end of the	Opening balance as at the beginning of	Ratio of	_
Items	Period	the Year	change	Reasons
C , , , , , , , , , , , , , , , , , , ,	2,485,783,000.50	4,972,524,758.70	-50%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Tr   bt	1,316,781,579.78	907,307,576.06	45%	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
$[L_{-},\mathcal{E}_{-},\mathcal{E}_{+}]_{[b]_{L}}$	7,615,057.77	17,674,707.55	-57%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
I   . t *pl.   .	2,368,367,750.12	1,752,799,860.87	35%	M
D1. m	42,946,124.18	29,475,413.33	46%	M
G All	2,710,407,586.05	1,661,770,763.96	63%	M <sub>1</sub> 1,
O , F, i #	236,069,350.21	100,654,101.39	135%	M
D W m	72,033,067.63	31,482,514.80	129%	M
$S_{-},\mathcal{F}_{-},\mathcal{F}_{m,l^{\prime},l^{\prime}}.$	1,199,559,074.08	519,422,250.00	131%	$M_{1} = \begin{bmatrix} x_{1} & x_{2} & x_{3} & x_{4} \\ x_{1} & x_{2} & y_{1} & x_{2} & x_{3} \end{bmatrix} = \begin{bmatrix} x_{2} & x_{3} & x_{4} \\ x_{1} & x_{2} & x_{3} \end{bmatrix} = \begin{bmatrix} x_{1} & x_{2} & x_{3} \\ x_{1} & x_{2} & x_{3} \end{bmatrix}$
$D^{r-r} = \sum_{l \in I} \rho_l r$	12,240,519.57	4,725,748.28	159%	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$O_{-},\mathcal{F},\iota(\mathcal{H})=\mu_{1}(\mathfrak{b}_{\lambda}\mu_{\lambda})$	33,196,473.53	526,384,431.15	-94%	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

	Income Statement				
	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of		
Items	(Jan – Sep)	(Jan – Sep)	change	Reasons	
Q . F . r . £ r .	7,070,780,938.31	5,387,845,935.96	31%		
Q . * T	3,957,631,876.59	3,005,217,397.09	32%	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	
$\left[\frac{ I_i }{e^{ I_i }}, \left(\mathbb{H}_{\mathbb{R}^n}^{-n}, \frac{ I_i }{ I_i }, \frac{ I_i }{ I_i }\right)\right]$	39,511,717.28	-14,636,854.56	N/A	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Im	313,206,671.22	202,061,631.73	55%	$\begin{bmatrix} M_{1} & 1 & \cdots & M_{n} & K_{1} & \cdots & M_{n} & \cdots & M_$	
$N_{i,j} = \sum_{i,j} f_{i,j,k} \left( 1 - f_{i,j,j,j} \right) \cdot 1 \cdot \mathbf$	72,257,721.95	33,558,889.22			
$O \to k \oplus^m (k) \oplus^{r_1 \times r_2 \times r_3 \times r_4} \oplus^m$	285,252,496.15	-436,322,994.17	N/A	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	

Statement of Cash Flow				
	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of	
Items	(Jan – Sep)	(Jan – Sep)	change	Reasons
$N_{i} = \begin{bmatrix} 1 & 1 & 1 & 1 \\ 1 & 1 & 1 & 1 \end{bmatrix} \times \begin{bmatrix} T_{i} \\ T_{i} \end{bmatrix} $	-1,757,461,995.58	-368,977,652.38	376%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

3.2  $A_{-|1|}$   $A_{-|$ 

- - $\square A = \mu \cap_{[b]} b_{[b]} = \sqrt{|N_b|} \cdot A = \mu \cap_{[b]} b_{[b]}$

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Luli F. F. . . . : Chen Qiyu
30 O. b. F 2013

#### **§4 APPENDICES**

#### 4.1 Consolidated balance sheet

30 2013

# $P_{a} = \mathcal{F}_{b}$ : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

 $C_{\lambda}: \Gamma_{\lambda} : C_{\lambda} : RMB \quad T_{\lambda} : \Gamma_{\lambda}: \Gamma_{\lambda}: \Gamma_{\lambda}$ 

<u> </u>		'   '
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C <sub>1</sub> , , • • • • • • • • • • • • • •	2,485,783,000.50	4,972,524,758.70
S. t.m. X.X.		
$L_1, \ldots, b_1, \ldots, t_{N-1}, \ldots, t_{N-1}, \ldots, t_{N-1}, \ldots$		
$\mathbf{F}_{\mathbf{r}_1, \dots, \mathbf{r}_{k-1}}^{\mathbf{r}_{k-1}} \dots \mathbf{F}_{\mathbf{r}_{k-1}}^{\mathbf{r}_{k-1}} \mathbf{f}^{\mathbf{r}_{k-1}}$	258,756,754.96	224,834,307.14
$B_{\text{eff}} = \mathcal{F}_{\text{eff}}^{-1} + b_{\text{ff}}$	293,416,923.81	306,710,161.00
$T_{i}^{F}$ , $f_{i}$ , $f_{i}$ , $h_{i}$	1,316,781,579.78	907,307,576.06
PL 1 mr.	279,681,295.65	239,307,192.55
Pr m' m r bt		
$R_{\lambda}$ , $r_{1}^{\mu}$ , $r_{1}^{\mu}$ , $r_{2}^{\mu}$ , $r_{3}^{\mu}$ , $r_{3}^{\mu}$		
$R_{1}$ , $r_{1}^{2}$ , $r_{2}^{2}$ , $r_{3}^{2}$ , $r_{4}^{2}$ , $r_{5}^{2}$ , $r_{5}^{2}$ , $r_{5}^{2}$ , $r_{5}^{2}$		
$\mathbf{L}_{i} \cdot \mathcal{E}_{i} \cdot \mathcal{E}_{i \cdot \lambda_{i} \cdot \mathbf{b}_{k}}$	7,615,057.77	17,674,707.55
$D_{i_1} \dots E_{i_{l_1} \mid b_l}$	15,697,156.84	12,298,837.25
O FE Library	467,158,390.71	423,080,420.35
Pr.F. in the contract of		
I	1,629,432,467.70	1,273,438,729.51
N ( #		
0 , 月, 1 既,	4,495,956.06	4,341,123.93
T	6,758,818,583.78	8,381,517,814.04
Non-current assets:		
Pr		
A white the second of	1,665,410,046.04	1,454,122,878.62
H <sub>1</sub> 1		
L. 1 - , £., £ , hr.		
L 1 - , F	9,668,859,344.13	8,593,169,673.95
I	, , ,	, , ,
F <sub>1</sub> , ,	2,987,437,844.46	2,595,295,851.85
C A	1,055,727,109.86	881,963,019.2354,1
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,
L. 1 - 1, F <sub>m</sub> 3( , L. 1)7 , - m 9(f. 10,(118(15,69)791(5,0)7.4.07.77)-64144,142[(139,68	8)7887	
(1) 1 (1) 1		
ı	1	

#### **Consolidated balance sheet (Continued)**

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Non-current assets (Continued):	5.14 O 5.10 1 5.10 4	1001
D lt.	72,033,067.63	31,482,514.80
O , F , , , - , t # , , , .	236,069,350.21	100,654,101.39
T. 11 1 M	20,830,762,112.56	17,125,622,651.97
T	27,589,580,696.34	25,507,140,466.016
11	, , ,	, , ,

#### **Consolidated balance sheet (Continued)**

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
$P_{1\lambda} = \sum_{i=1}^{n} \frac{1}{i!} \left( \left( f_{i} - \frac{1}{i!} f_{i-1} \right) \right)$	2,240,462,364.00	2,240,462,364.00
$C_{r,\lambda+1}^{\dagger}(\xi_r,\xi_r^{\dagger})$	4,396,998,107.25	4,287,287,930.01
L' : £, (£ , £		
Santa Karta		
Six p X . X .	1,338,476,598.49	1,338,476,598.49
$G_{ij} f_{ij} f_{ij} f_{ij} f_{ij}$		
, , , , , , , , , , , , , , , , , , ,	6,621,610,997.36	5,703,028,462.15
E. 大, , , , , , , , , , , , , , , , , , ,	-4,289,492.31	-10,462,767.38
$T_{i+1}, \Psi_{i+1}, f_{ij+1}, f_{ij+1}, \dots, f_{i+1}, f_{i+1}, \dots, f_{i+1}, \dots$	14,593,258,574.79	13,558,792,587.27
$M_{i}$ , $f_{i}$ , $f_{i}$ , $f_{i}$	1,889,445,595.04	1,745,855,848.86
$T_{c+1}, \Psi_{c+1}, f_{b'+b_1}, \dots, f$	16,482,704,169.83	15,304,648,436.13
T. I h b h r i · · · · · · · · · · · · · · · · · ·	27,589,580,696.34	25,507,140,466.01

$$\begin{array}{c|c} C_{m+1} & C_{m+1}$$

$$C \underset{H_{i} \rightarrow I}{\overset{r}{\longrightarrow}} F_{i, i} \underset{r}{\overset{r}{\longrightarrow}} J_{i, j} O \underset{r}{\overset{r}{\longrightarrow}} \mathcal{F}:$$

#### **Balance sheet of the Parent Company**

30 2013

# $P_{a} = \mathcal{F}_{b}$ : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

 $C_{\lambda}: \Gamma_{\lambda}: C_{\lambda} \times C_{\lambda} \times C_{\lambda}: RMB \to C_{\lambda} \times C_{\lambda}: \Gamma_{\lambda}: \Gamma_{\lambda}$ 

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C, , , , , , , , , , , , , , , , , , ,	967,810,425.06	2,804,108,583.37
$\mathbf{F}_{r_1, \ldots, r_{k-1}}^{l_1, \ldots, l_{k-1}} = \mathbf{F}_{r_k, \ldots, r_{k-1}}^{l_1, \ldots, l_k} \mathbf{F}_{r_k, \ldots, r_k}^{l_k}$		
$B_{\text{All}} = \mathcal{F}_{\text{total}}^{\text{total}} b_{\text{le}}$		
Tr t be		
Pr		
I. E. E. Libe	112,185,785.22	98,972,778.68
$D_{i_1, \dots, i_{r-1}, i_1} b_{i_r}$	24,240,000.00	
0 . F.F	1,207,151,982.57	941,562,545.17
$I_1,\ldots,I_{k'}$	517,042.01	516,409.53
N., -, ( #., , ), ( , , ), f		
O , F, ( # , )	280,000,000.00	250,000,000.00
T <sub>1</sub> : ( 既 , ) ,	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
A 14 61-15-16 11-11-11		
H. 1 m + f m		
$L_{c,1}$ - $\mathcal{F}_{m}^{-1}\mathcal{F}_{c,1}$ $\mathcal{F}_{k}$		
L. 1 - , F <sub>m</sub> , q <sub>1</sub> , ' <sub>1</sub> ,	5,471,340,934.74	4,173,763,622.82
I., m., F., F.		
F	20,153,012.47	20,815,349.96
C		
Pr		
D,		
Pr. 1. A. B. L. L. L.		
O <sub>11</sub> . r ' '		
I r . bp	3,215,662.67	3,496,198.41
D		
G		
L., t = , F <sub>m</sub> , , , FF , , , , , , , , , , , , , , ,		
D. 'W		
0 , f 1 ff	4,470,831,299.40	4,035,133,683.09
T. 1, 1 75,	9,965,540,909.28	8,233,208,854.28
T	12,557,446,144.14	12,328,369,171.03

#### **Balance sheet of the Parent Company (Continued)**

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
S . F F <sub>m. F . 1</sub> .		
F. T. Lindson of the state of t		
B <sub>M</sub> = 1 b <sub>1</sub>		
$T^{r}$ $b_{l}$		
$R_{\cdots k}^{\dagger}$		
/_tb	26,138,331.81	29,108,232.08
$T_{1}$ , $b_{1}$	16,833,088.84	5,188,721.77
I, Y, , PP	155,509,208.37	152,405,396.96
D		
0 .F.   bt	554,584,851.12	46,800,203.98
No1 K. h bake to be seen of	360,000,000.00	355,000,000.00
O F. M. H. B. L.		499,375,000.00
T. L. H. S. L. B. B. L.	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
L., t -, f <sub>m+1</sub> .	125,000,000.00	165,000,000.00
B	4,070,832,033.25	4,063,347,254.54
L. r - , f <sub>m</sub> + + b <sub>l</sub>		
Something		
A. A. Lib.L.		
D		
O . F 1 M	2,275,000.00	2,500,000.00
Т 1 Ж	4,198,107,033.25	4,230,847,254.54
Т	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):	2 240 462 264 00	2 2 10 1 (2 2 ( 1 0 0
P - ( f   f   + 1)	2,240,462,364.00	2,240,462,364.00
C, , , , , , , , , , , , , , , , , , ,	3,754,014,307.53	3,755,009,519.04
L' ' K   K   K   K   S   K   K   K   K   K		
Strain to the	205 (25 420 (0	205 (25 420 (0
St. J. J. J.	305,635,420.68	305,635,420.68
$G_{ij} = \frac{f_{ij} - f_{ij}}{f_{ij}} = \frac{f_{ij}}{f_{ij}}$	946,161,538.54	700 527 057 00
T. M. Fu b. F(fm . Fu b. F. f)	7,246,273,630.75	708,537,057.98 7,009,644,361.70
1 T 1 10 Up	1,240,213,030.13	7,009,044,301.70
$= \frac{T_{-\frac{1}{2}\frac{K}{2}} b_{1}b_{2} }{\sum_{i=1}^{k}(-1)^{k}} \cdots \Psi_{i} = \frac{f_{i}b_{i} }{\sum_{j=1}^{k}(-1)^{k}} b_{1}  \cdots \cdots F_{i}  (f_{i}\Psi_{i}) = \frac{f_{i}b_{i} }{\sum_{j=1}^{k}(-1)^{k}} b_{1}  \cdots \cdots F_{i}  (f_{i}\Psi_{i}) = \frac{f_{i}b_{i} }{\sum_{j=1}^{k}(-1)^{k}} b_{1}  \cdots F_{i} $	12,557,446,144.14	12,328,369,171.03

$$C = F_{i_1, \dots, i_{j-1}, \dots, i_{j-1}} O = F_{i_1, \dots, i_{j-1}, \dots, i_{j-1}} O$$

#### 4.2

#### **Consolidated Income Statement**

# $P \not\vdash_b : \textbf{Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*}$

			l l		I
	Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I.	$T_{i+1} \ldots , \mathcal{F}_{i,\lambda}, \iota \in \mathcal{F}_{i,\lambda}, \iota$	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
	I., ( ), ( ), ( ), ( ), ( ), ( ), ( ), (	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
	I K m.				
	E. F F. m. I m				
	F.,				
II.	T	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
	I., [1], (1), (0), (#), (1)	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
	Ι.Χ				
	F.,				
	P.E. mir m. E. r.				
	C. m				
	$N_{r} = \frac{\mathcal{F}_{r}}{r} \cdot \cdot \cdot \cdot \cdot \cdot \frac{\mathcal{F}_{r}}{r} \cdot \cdot \cdot \cdot \mathcal{F}_{r}$				
	P. 1				
	17 7 7 111				
	$\mathbf{A}_{\mathbf{m}} \stackrel{\mathcal{F}_{\mathbf{a}}}{\leftarrow} \stackrel{\mathcal{F}_{\mathbf{a}}}{\leftarrow} \stackrel{i \not = 1}{\leftarrow} \cdots$				
	Br.,, , , , , , , , , , , , , , , , , , ,	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
	S. no. 1	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
	A	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
	F	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
	A	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
	$P_{l'}:G_{l',l',m,n-l',l',n-l',l',l'}$	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
	I . m · . · · m ("–"	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
	$I_{\cdots p^{r-1}}:G_{p^{r-1}}\to m$				
	·· m   · › · · · · · · · · · · / · · · / · · / /	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
	F. た				
III.	O f. , r f. , ("=" , , . , . , . , )	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
	P <sub>1</sub> : N., -, , , , , , , , , , , , , , , , , ,	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
	L. : N	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
	I. p. r: L. '	260,198.27	-243,201.72	979,886.77	946,040.98

#### **Income Statement of the Parent Company**

J  $\mathcal{C}_{m}$ 

### $P_{x_{a_1}, x_{a_2}, x_{a_3}}$ : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

		I	l	_
Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
$I_{i} = Q_{i} \mathcal{F}_{i-\lambda}^{\dagger} (i - \mathcal{F}_{i-\lambda}, i)$				
L. Q. F				
Br , r £ ft,				
S. III.				
A FALLER	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
F	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
A m pm t				
$P_{l'}: G \xrightarrow{r} f \underset{r \to r+r}{\xrightarrow{r}} f \underset{r \to r}{\xrightarrow{r}} f \xrightarrow{r} f$				
I m m. ("-"	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
I, ,   , , , ; G   , , , , , , , , , , , , , , , , , ,	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Q. F. ("-", -1, -1, -1, -1, -1, -1, -1, -1, -1, -1	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
$P_{l^{1}}:N_{\ldots}$ , $\mathcal{F}_{l^{1}}$ , $l^{1}$ , $\mathcal{F}_{l^{1}}$ , $l^{2}$	76,900.00	234,093.38	236,049.11	734,093.38
$\mathbf{L}_{i}^{2}:\mathbf{N}_{i}$ , $\mathbf{L}_{i}$ , $\mathbf{L}_{i}$		-570,000.00	2,514,544.42	860,000.00
I, p, , : L, , , , , , , , , , , , , , , , ,			5,725.77	
III. $T_{i+1}^{-1}$ , $f_{i-1}$ ("-",	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
L. : I m				
J. N. F. ("-",	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
$(1)  b_1 , \dots, \xi_{r-1} , \dots, \xi_{r-1} , \xi_{r-1} $				
$(2) \qquad \begin{matrix} \downarrow \\ \downarrow \end{matrix} \qquad \begin{matrix} \downarrow \end{matrix} \qquad \begin{matrix} \downarrow \\ \downarrow \end{matrix} \qquad \begin{matrix} \downarrow \end{matrix} \qquad \begin{matrix} \downarrow \\ \downarrow \end{matrix} \qquad \begin{matrix} \begin{matrix} \downarrow \end{matrix} \qquad \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \downarrow \end{matrix} \qquad \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \downarrow \end{matrix} \qquad \end{matrix} \end{matrix} \qquad \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \downarrow \end{matrix} \qquad \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \begin{matrix} \downarrow \end{matrix} \end{matrix} \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \downarrow \end{matrix} \end{matrix} \end{matrix} \end{matrix} \end{matrix} \end{matrix} \end{matrix} \end{matrix} \qquad \begin{matrix} \begin{matrix} \begin{matrix} \downarrow \end{matrix} \end{matrix}$				
I. O F. m F m			51,779.40	27,699,470.25
. II. T. 11. m F m	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

$$\frac{L_{\text{eff}}}{C_{\text{eff}}} \frac{1}{m} \frac{R_{\text{eff}}}{R_{\text{eff}}} \stackrel{\mathcal{F}}{\longrightarrow} \frac{1}{C_{\text{eff}}} \stackrel{\mathcal{F}}{\longrightarrow} \frac{1}{Q_{\text{eff}}} \stackrel{\mathcal{F}}{\longrightarrow} \frac{1}{Q_{\text{eff$$

$$C \underset{H_{i} \to I}{\overset{r}{\longrightarrow}} F_{i, j} \underset{i \to i}{\overset{r}{\longrightarrow}} J_{i, j} O \underset{i \to i}{\overset{r}{\longrightarrow}} \mathcal{F}$$

#### **Consolidated Statement of Cash Flow**

J .€ –

2	1	7	2
_	U	1	J

#### **Consolidated Statement of Cash Flow (Continued)**

J  $\mathcal{C}_{r}$ 2013

	Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
II.	Cash flow generated from investing activities (Continued):		
	C	711,664,658.89	839,693,736.40
		251,949,461.45	734,761,521.45
	$N_{-1}$ , $\xi_1$ , $\xi_2$ , $\xi_3$ .		
	N	2,011,879,515.78	
	O.F. SIAFINISH STAN	100,020,349.23	9,072,797.31
	Sib	3,075,513,985.35	1,583,528,055.16
	N Land Emp It was	-1,757,461,995.58	-368,977,652.38
III.	Cash flow generated from financing activities:		
	C F F m - r f b'	2,088,710.98	761,199.00
	Lipidia English to by the Emple me a month of	2,088,710.98	761,199.00
	C	1,302,361,982.24	1,022,152,808.76
	$C_1 = \mathcal{E}_{\cdots \lambda}$ . $\mathcal{E}_{m \lambda} = \Gamma_{\lambda} = 0$ .		1,486,950,000.00
	$0$ , $\mathcal{E}_{i_1}$ , $\mathcal{E}_{i_2}$ , $\mathcal{E}_{j_1}$ , $\mathcal{E}_{i_2}$ , $\mathcal{E}_{i_3}$ , $\mathcal{E}_{i_4}$ , $\mathcal{E}_{i_4}$ , $\mathcal{E}_{i_5}$ , $\mathcal{E}_{i_5}$ , $\mathcal{E}_{i_5}$	329,448,475.13	262,541,891.46
	Sib-11	1,633,899,168.35	2,772,405,899.22
	C <sub>1</sub> × 1, b · t·m·	1,221,891,677.53	2,628,044,486.20
	$C$ , $F$ , $F_{b'}$ , $F$ , $F$ , $F$ , $F$ , $F$	950,844,046.86	601,916,917.03
	Lyran: A same to the same to t	702,264,204.84	366,813,171.49
	O F. TA FILE CALLED	48,488,630.70	101,408,014.93
	Si b	2,221,224,355.09	3,331,369,418.16
	N f. f. f. f. marriage	-587,325,186.74	-558,963,518.94
IV.	Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V.	Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
	P <sub>1</sub> : O	4,171,574,742.12	2,428,219,484.36
VI.	Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

$$\begin{array}{cccc} C_{\lambda} & F_{\lambda} & & \\ H_{\lambda} & & & \lambda & \\ \end{array} \begin{array}{cccc} J_{\lambda} & O_{\lambda} & \mathcal{F}_{\lambda} \end{array}$$

#### Statement of Cash Flow of the Parent Company

*J* € – 2013

# Pf. 1 b : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

 $C_{i}: C_{i} \times C_{i}$ 

<b>A</b>		
Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Cash flow generated from operating activities:		
$\frac{C_{1} - \mathcal{F}_{1} \cdot \mathcal{F}_{1}}{R_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1}} \cdot \frac{\mathcal{F}_{1} \cdot \mathcal{F}_{2}}{R_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1}} \cdot \frac{\mathcal{F}_{1} \cdot \mathcal{F}_{2}}{R_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{1}}{R_{1} \cdot \Gamma_{1} \cdot \Gamma_{1} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{2}}{R_{1} \cdot \Gamma_{1} \cdot \Gamma_{2} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{2}}{R_{1} \cdot \Gamma_{2} \cdot \Gamma_{2} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{2}}{R_{1} \cdot \Gamma_{2} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{2}}{R_{1} \cdot \Gamma_{2} \cdot \Gamma_{2}} \cdot \frac{\mathcal{F}_{1} \cdot \Gamma_{2}}{R_{1} \cdot \Gamma_{2}$		
O. F. F. J. Fan C. J. F. C. L. A. J.	37,439,681.37	40,008,504.21
Sib Lange Emissiphing	37,439,681.37	40,008,504.21
C		
C	47,805,533.82	43,283,375.23
T	20,609,862.43	11,891,537.59
O. F. L.	31,711,001.63	44,174,769.12
Sib-compared to the first state of the state	100,126,397.88	99,349,681.94
N. T. J.	-62,686,716.51	-59,341,177.73
II. Cash flow generated from investing activities:		

#### **Statement of Cash Flow of the Parent Company (Continued)**

J  $\mathcal{C}_{r}$ 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
III. Cash flow generated from financing activities:		
C Fine Emily Above		
$C_1 = \mathcal{K}_{1 \dots 1} = \mathcal{K}_{\frac{m}{m}} \frac{1}{p} \mathcal{K}_{1 \dots 1}$	255,115,078.77	
$C_1^{\prime} = \mathcal{K}_{m_{\lambda}} + \mathcal{K}_{m_{\lambda}}^{\prime} + \mathcal{K}_{m_{\lambda}} + \mathcal{K}_{m_{\lambda}}$		1,486,950,000.00
O .f., f., f., f., f., property	1,904,031,173.98	4,295,169,165.49
Sib-11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2,159,146,252.75	5,782,119,165.49
C the state of the	790,115,078.77	454,000,000.00
$C_{1}^{\prime}$ , $F_{2}$ , $F_{3}$ , $F_{4}$ , $F_{5}$ , $F_{7}$ , $F_{8}$	674,744,025.09	302,177,196.32
0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	2,109,471,293.35	5,478,222,986.00
Sib	3,574,330,397.21	6,234,400,182.32
N I. I	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
P <sub>L</sub> : Q	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

$$\begin{array}{cccc} C & F_{i_1} & F_{i_2} & \cdots & F_{i_{l-1}} & O & \cdots & F_{i_{l-1}} \\ H_{i_{l-1}} & \cdots & I_{i_{l-1}} & J_{i_{l-1}} & \end{array}$$